scholarly journals Squamous Cell Carcinoma (Marjolin’s Ulcer) Arising in a Sacral Decubitus Ulcer Resulting in Humoral Hypercalcemia of Malignancy

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
John T. O’Malley ◽  
Candace Schoppe ◽  
Sameera Husain ◽  
Marc E. Grossman
Keyword(s):  
Squamous Cell Carcinoma ◽  
Parathyroid Hormone ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Decubitus Ulcer ◽  
Humoral Hypercalcemia Of Malignancy ◽  
Hypercalcemia Of Malignancy ◽  
Humoral Hypercalcemia ◽  
Marjolin’S Ulcer ◽  
Parathyroid Hormone Related Peptide

Long-standing burns, fissures, and ulcers that undergo malignant transformation into a variety of malignancies, including squamous cell carcinoma, is commonly referred to as a Marjolin’s ulcer. It is well recognized that squamous cell carcinomas of the lung and esophagus can cause humoral hypercalcemia of malignancy secondary to paraneoplastic secretion of parathyroid hormone-related peptide. However, it is extremely rare for a squamous cell carcinoma developing in a sacral decubitus ulcer to cause humoral hypercalcemia of malignancy. We describe the first case of a patient found to have elevated serum levels of parathyroid hormone related peptide related to his Marjolin’s ulcer. A 45-year-old African American man with T6 paraplegia and a sacral decubitus ulcer present for 20 years was admitted for hypercalcemia of unclear etiology. He was subsequently found to have elevated parathyroid hormone related peptide and an excisional biopsy from the ulcer showed invasive squamous cell carcinoma suggestive of humoral hypercalcemia of malignancy. The patient ultimately succumbed to sepsis while receiving chemotherapy for his metastatic squamous cell carcinoma. Humoral hypercalcemia of malignancy is a rare and likely underrecognized complication that can occur in a Marjolin’s ulcer.

scholarly journals A CASE OF RENAL PELVIC SQUAMOUS CELL CARCINOMA ACCOMPANIED WITH HUMORAL HYPERCALCEMIA OF MALIGNANCY

1991 ◽  
Vol 82 (8) ◽  
pp. 1305-1308
Author(s):  
Wataru Sakamoto ◽  
Taketoshi Kishimoto ◽  
Tatsuya Nakatani ◽  
Manabu Kouno ◽  
Masanobu Maekawa ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Humoral Hypercalcemia Of Malignancy ◽  
Hypercalcemia Of Malignancy ◽  
Humoral Hypercalcemia

Immunohistochemical Detection of Parathyroid Hormone–Related Protein in a Cutaneous Squamous Cell Carcinoma Causing Humoral Hypercalcemia of Malignancy

1999 ◽  
Vol 123 (8) ◽  
pp. 725-730
Author(s):  
Manuel Crespo ◽  
Bernardo Sopeña ◽  
John J. Orloff ◽  
Jorge F. Cameselle Teijeiro ◽  
Pamela Dann ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Parathyroid Hormone ◽  
Squamous Cell ◽  
Cutaneous Squamous Cell Carcinoma ◽  
Squamous Cell Carcinomas ◽  
Related Protein ◽  
Humoral Hypercalcemia Of Malignancy ◽  
Hypercalcemia Of Malignancy ◽  
Humoral Hypercalcemia ◽  
Parathyroid Hormone Related Protein

Abstract Humoral hypercalcemia of malignancy is a cancer-related hypercalcemia caused by production of humoral factors by malignant cells in patients without bone metastases. Squamous cell carcinomas are the tumors most frequently associated with humoral hypercalcemia of malignancy, and parathyroid hormone–related protein is the main humoral factor implicated. In spite of the fact that normal keratinocytes produce parathyroid hormone–related protein, it is highly unusual for patients with squamous cell carcinomas of the skin to present with humoral hypercalcemia of malignancy. We present a well-documented case of cutaneous squamous cell carcinoma complicated by hypercalcemia in a patient with high levels of plasma parathyroid hormone–related protein and immunohistochemical evidence of high parathyroid hormone–related protein production by the tumoral cells.

scholarly journals Squamous cell carcinoma which combined humoral hypercalcemia of malignancy.

Skin Cancer ◽  
1992 ◽  
Vol 7 (3) ◽  
pp. 276-280 ◽  
Author(s):  
Naoki MAEKAWA ◽  
Koichi NAKAGAWA ◽  
Chihiro NAKAMOTO ◽  
Masayoshi FURUKAWA ◽  
Toshio HAMADA
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Humoral Hypercalcemia Of Malignancy ◽  
Hypercalcemia Of Malignancy ◽  
Humoral Hypercalcemia

scholarly journals SAT-120 Humoral Hypercalcemia of Malignancy Caused by Squamous Cell Carcinoma of the Penis

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Romana Kanta ◽  
Mohammad Jamal Uddin Ansari ◽  
Mariam Ali ◽  
Anis Rehman ◽  
Hadoun Jabri ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Calcium Level ◽  
The United States ◽  
Squamous Cell Carcinomas ◽  
Penile Carcinoma ◽  
Humoral Hypercalcemia Of Malignancy ◽  
Hypercalcemia Of Malignancy ◽  
Humoral Hypercalcemia

Abstract Background. Humoral hypercalcemia of malignancy (HHM) accounts for approximately 80% of hypercalcemia associated with cancer. We present an unusual case of HHM caused by recurrent squamous cell carcinoma of the penis. Case. A 45 year old male was brought to the emergency department (ED) due to worsening confusion over 48 hours. History was notable for squamous cell carcinoma of the penis initially diagnosed 12 years ago and managed by partial penectomy and ilioinguinal lymphadenectomy. Recurrence had been diagnosed approximately 30 days before presentation to the ED. The patient was somnolent, disoriented, and unable to follow commands. Admission laboratories were remarkable for new occurrence of hypercalcemia (serum calcium corrected for low albumin 17.0 mg/dL, 8.6–10.3) and acute renal failure (Cr 1.7 mg/dL, 0.6–1.3; BUN 44 mg/dL, 7–25). No masses or hemorrhages were observed on head imaging, though computed tomography of the chest, abdomen, and pelvis revealed multiple lung and liver masses and lytic bone lesions. Biopsy of a rib mass confirmed metastatic squamous cell carcinoma. Intact PTH level was suppressed at 1 pg/mL (12–88), but parathyroid hormone related protein (PTHrP) was significantly elevated at 120 pM (0.0–2.3). HHM due to PTHrP was diagnosed. Corrected calcium level reached a nadir of 9.5 mg/dL on hospital day seven after saline hydration, calcitonin, and zoledronic acid, but high dose denosumab (120 mg weekly) was started hospital day 10 after corrected calcium level increased to 11.7 mg/dL. Despite corrected calcium levels consistently in the range of 10.5–11.5 mg/dL for the remainder of hospitalization, the patient’s mental status failed to improve. He expired on hospital day 24. Conclusions. Squamous cell carcinoma of the penis is rare in the United States, with only about 2,000 cases diagnosed annually. Though squamous cell carcinomas are collectively the most common cause of PTHrP-related hypercalcemia, there are only a few cases of PTHrP-related hypercalcemia due to squamous cell carcinoma of the penis documented in the peer reviewed literature. As in our patient’s case, other penile carcinoma patients with PTHrP-related hypercalcemia have had regionally advanced or metastatic disease and limited therapeutic response to bisphosphonates. Our patient’s survival after occurrence of hypercalcemia was also similar to other published cases of penile carcinoma complicated by PTHrP-related hypercalcemia. This case confirms the potential for penile carcinoma to cause HHM through hypersecretion of PTHrP like squamous cell carcinomas of the lung, head, and neck. Denosumab may be a more effective treatment option than a bisphosphonate based on the therapeutic experience in this case and others. PTHrP-related hypercalcemia appears to be a strong indicator of limited life expectancy for penile carcinoma as for other malignancies.

Sign in / Sign up

Export Citation Format

Share Document